×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LPCN – lipocine inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LPCN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/16
08:27 am
lpcn
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone [Yahoo! Finance]
Neutral
Report
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone [Yahoo! Finance]
12/16
08:00 am
lpcn
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Low
Report
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
12/9
04:25 pm
lpcn
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
11/25
01:53 pm
lpcn
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
11/18
08:26 am
lpcn
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) [Yahoo! Finance]
Medium
Report
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) [Yahoo! Finance]
11/18
08:00 am
lpcn
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Medium
Report
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
11/13
08:11 am
lpcn
Lipocine (NASDAQ:LPCN) had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
Lipocine (NASDAQ:LPCN) had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a "buy" rating on the stock.
11/12
01:27 pm
lpcn
Lipocine (NASDAQ:LPCN) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Lipocine (NASDAQ:LPCN) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/19
05:10 pm
lpcn
Form 4 Lipocine Inc. For: Dec 18 Filed by: Patel Mahesh V.
Low
Report
Form 4 Lipocine Inc. For: Dec 18 Filed by: Patel Mahesh V.
12/19
05:07 pm
lpcn
Form 4 Lipocine Inc. For: Dec 18 Filed by: Fogarty Krista
Low
Report
Form 4 Lipocine Inc. For: Dec 18 Filed by: Fogarty Krista
12/16
09:45 am
lpcn
Form 8-K Lipocine Inc. For: Dec 15
Low
Report
Form 8-K Lipocine Inc. For: Dec 15
12/15
04:06 pm
lpcn
Form 8-K Lipocine Inc. For: Dec 12
Neutral
Report
Form 8-K Lipocine Inc. For: Dec 12
12/11
05:01 pm
lpcn
Form 8-K Lipocine Inc. For: Dec 08
Low
Report
Form 8-K Lipocine Inc. For: Dec 08
11/18
09:32 am
lpcn
Form 8-K Lipocine Inc. For: Nov 18
Medium
Report
Form 8-K Lipocine Inc. For: Nov 18
11/18
09:30 am
lpcn
Form 8-K Lipocine Inc. For: Nov 18
Medium
Report
Form 8-K Lipocine Inc. For: Nov 18
11/6
09:40 am
lpcn
Form 8-K Lipocine Inc. For: Nov 06
Low
Report
Form 8-K Lipocine Inc. For: Nov 06
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/24
Lipocine Announces Regulatory Path Forward for TLANDO™ Resubmission
65.6%
2/25 Lipocine Announces $6 Million Registered Direct Offering Priced At-The-Market 13.8%
1/1 LIPOCINE EQUITY LOSS ALERT: ROSEN, A LEADING LAW FIRM, Reminds Lipocine Inc. Investors of Important January 14th Deadline in Securities Class Action - LPCN 8.9%
1/10 Form 8-K Lipocine Inc. For: Jan 10 8.0%
5/14 Lipocine Announces TLANDO™ NDA PDUFA Action Date of November 9, 2019 7.2%
4/10 Investors Who Bought Lipocine (NASDAQ:LPCN) Shares Five Years Ago Are Now Down 94% [Yahoo! Finance News] 6.8%
4/17 Form 8-K Lipocine Inc. For: Apr 17 6.2%
3/4 Lipocine Announces TLANDO™ PDUFA Date of August 28, 2020 6.1%
8/7 Q2/2019 6/30/2019 EPS -0.140 ZacksConsensus -0.220 ActVsEst 0.080 - Beat 5.6%
2/5 Form 8-K Lipocine Inc. For: Feb 05 4.7%
2/25 Lipocine Announces $6 Million Registered Direct Offering Priced At-The-Market 13.8%
1/1 LIPOCINE EQUITY LOSS ALERT: ROSEN, A LEADING LAW FIRM, Reminds Lipocine Inc. Investors of Important January 14th Deadline in Securities Class Action - LPCN 8.9%
1/10 Form 8-K Lipocine Inc. For: Jan 10 8.0%
5/14 Lipocine Announces TLANDO™ NDA PDUFA Action Date of November 9, 2019 7.2%
4/10 Investors Who Bought Lipocine (NASDAQ:LPCN) Shares Five Years Ago Are Now Down 94% [Yahoo! Finance News] 6.8%
4/17 Form 8-K Lipocine Inc. For: Apr 17 6.2%
3/4 Lipocine Announces TLANDO™ PDUFA Date of August 28, 2020 6.1%
8/7 Q2/2019 6/30/2019 EPS -0.140 ZacksConsensus -0.220 ActVsEst 0.080 - Beat 5.6%
2/5 Form 8-K Lipocine Inc. For: Feb 05 4.7%
TOP News Decliners
11/11
Lipocine Receives Complete Response Letter for TLANDO™ from U.S. FDA
-72.0%
11/13 Lipocine Announces Launch Of Public Offering Of Common Stock And Warrants -40.9%
3/13 Form 10-K Lipocine Inc. For: Dec 31 -18.9%
7/23 Form 8-K Lipocine Inc. For: Jul 23 -17.8%
11/12 Form 8-K Lipocine Inc. For: Nov 12 -14.5%
4/1 Form 8-K Lipocine Inc. For: Apr 01 -11.8%
4/21 Form 8-K Lipocine Inc. For: Apr 21 -10.2%
11/12 Form 8-K Lipocine Inc. For: Nov 11 -9.7%
1/13 TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lipocine Inc. and Encourages Investors with Losses to Contact the Firm -8.9%
11/14 Form 424B5 Lipocine Inc. -8.5%
11/13 Lipocine Announces Launch Of Public Offering Of Common Stock And Warrants -40.9%
3/13 Form 10-K Lipocine Inc. For: Dec 31 -18.9%
7/23 Form 8-K Lipocine Inc. For: Jul 23 -17.8%
11/12 Form 8-K Lipocine Inc. For: Nov 12 -14.5%
4/1 Form 8-K Lipocine Inc. For: Apr 01 -11.8%
4/21 Form 8-K Lipocine Inc. For: Apr 21 -10.2%
11/12 Form 8-K Lipocine Inc. For: Nov 11 -9.7%
1/13 TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lipocine Inc. and Encourages Investors with Losses to Contact the Firm -8.9%
11/14 Form 424B5 Lipocine Inc. -8.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: